Inventiva (IVA) has released an update.
Inventiva, a biopharmaceutical company, has announced the availability of documents for its upcoming Combined General Meeting on June 20, 2024, urging shareholders to participate. The company specializes in developing oral therapies for metabolic dysfunction-associated steatohepatitis (MASH/NASH) and other diseases lacking effective treatments. Inventiva is progressing with a pivotal Phase III clinical trial for its leading candidate, lanifibranor, targeting MASH/NASH, and is exploring further development opportunities.
For further insights into IVA stock, check out TipRanks’ Stock Analysis page.
